Sarcoma  >>  depatuxizumab mafodotin (ABT-414)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
depatuxizumab mafodotin (ABT-414) / AbbVie
Intellance1, NCT02573324 / 2015-001166-26: A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Checkmark From Intellance-1 trial in 1L GBM
May 2019 - May 2019: From Intellance-1 trial in 1L GBM
Completed
3
691
Europe, Canada, US, RoW
Temozolomide, Depatuxizumab mafodotin, ABT-414, Radiation, Placebo for ABT-414
AbbVie, Radiation Therapy Oncology Group
Glioblastoma, Gliosarcoma
04/22
04/22

Download Options